Affiliation:
1. Department of Pharmacy Practice, Massachusetts General Hospital, Boston, MA
2. Department of Pharmacy Practice, Duquesne University, Pittsburgh, PA
3. Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ
Abstract
Abstract
Purpose
The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings.
Summary
The U.S. epidemic of opioid-related deaths has been driven by misuse of prescription opioids and, increasingly, illicit drugs such as heroin, fentanyl, and fentanyl analogs, necessitating a refocusing of treatment efforts on expanding access to life-saving, evidence-based OUD pharmacotherapy. Inpatient treatment of opioid withdrawal includes acute symptom control through a combination of nonopioid medications and long-term pharmacotherapy to lessen opioid craving and facilitate stabilization and recovery. Methadone and buprenorphine reduce opioid craving, increase treatment retention, reduce illicit opioid use, and increase overall survival. Buprenorphine has logistical advantages over methadone, such as greater flexibility of treatment setting and less risk of adverse effects. Studies have shown the efficacy of long-acting injectable naltrexone to be comparable to that of buprenorphine if patients are detoxified prior to initiation of therapy; however, patients with active OUD are often not able to complete the week-long period of opioid abstinence needed prior to initiation of naltrexone injections. Although buprenorphine is preferred by many patients and can be prescribed in office-based settings, there remains a paucity of physicians certified to prescribe it.
Conclusion
Buprenorphine has become the medication of choice for many patients with OUD, but its use is limited by the low number of physicians certified to prescribe the agent. Other agents studied for treatment of OUD include methadone and naltrexone.
Publisher
Oxford University Press (OUP)
Subject
Health Policy,Pharmacology
Reference38 articles.
1. Drug and opioid-involved overdose deaths—United States, 2013-2017;Scholl;MMWR Morb Mortal Wkly Rep.,2018
2. Turning the tide or riptide? The changing opioid epidemic;Kertesz;Subst Abus.,2017
3. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence;Mattick;Cochrane Database Syst Rev.,2009
4. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence;Mattick;Cochrane Database Syst Rev.,2014
5. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial;D’Onofrio;JAMA.,2015
Cited by
55 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献